Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472307 | 0.94 | CA1 (0.33) | KDM4EMAPTCA1CA2PKM | |
| SCHEMBL14780876 | 0.86 | KDM4E (0.30) | KDM4EMAPT | |
| SCHEMBL10144373 | 0.84 | PDK1 (0.35) | CA1CA2PDE3BPDE3A | |
| SCHEMBL10286735 | 0.84 | CA1 (0.37) | KDM4EMAPTCA1CA2PKM | |
| SCHEMBL472298 | 0.83 | CA1 (0.31) | CA1CA2RECQL | |
| SCHEMBL566522 | 0.82 | CA1 (0.35) | KDM4EMAPTCA1CA2 | |
| SCHEMBL3359275 | 0.82 | PDE3B (0.40) | KDM4EMAPTCA1CA2PKM | |
| SCHEMBL27911168 | 0.81 | KDM4E (0.33) | KDM4EMAPTCA1CA2PKM | |
| SCHEMBL10039281 | 0.81 | RAB9A (0.40) | CA1CA2RECQL | |
| SCHEMBL23784635 | 0.81 | RECQL (0.32) | CA1CA2PKMRECQLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029039-A1 | ANIMAL ECTOPARASITE-CONTROLLING AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029039-A1 | ANIMAL ECTOPARASITE-CONTROLLING AGENT | H1-3, EEF1A1, H1-4 | KDM4E 478/4885MAPT 3835/4885CA1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.